{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["dacarbazine", "galectin-3 Lectin", "melanoma", "oxidative stress", "quartz crystal microbalance (QCM)"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35886983", "DateCompleted": {"Year": "2022", "Month": "07", "Day": "28"}, "DateRevised": {"Year": "2022", "Month": "08", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "07", "Day": "11"}], "Language": ["eng"], "ELocationID": ["7635", "10.3390/ijms23147635"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "23", "Issue": "14", "PubDate": {"Year": "2022", "Month": "Jul", "Day": "11"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "MG-<i>Pe</i>: A Novel Galectin-3 Ligand with Antimelanoma Properties and Adjuvant Effects to Dacarbazine.", "Abstract": {"AbstractText": ["Melanoma is a highly metastatic and rapidly progressing cancer, a leading cause of mortality among skin cancers. The melanoma microenvironment, formed from the activity of malignant cells on the extracellular matrix and the recruitment of immune cells, plays an active role in the development of drug resistance and tumor recurrence, which are clinical challenges in cancer treatment. These tumoral metabolic processes are affected by proteins, including Galectin-3 (Gal-3), which is extensively involved in cancer development. Previously, we characterized a partially methylated mannogalactan (MG-<i>Pe</i>) with antimelanoma activities. In vivo models of melanoma were used to observe MG-<i>Pe</i> effects in survival, spontaneous, and experimental metastases and in tissue oxidative stress. Analytical assays for the molecular interaction of MG-<i>Pe</i> and Gal-3 were performed using a quartz crystal microbalance, atomic force microscopy, and contact angle tensiometer. MG-<i>Pe</i> exhibits an additive effect when administered together with the chemotherapeutic agent dacarbazine, leading to increased survival of treated mice, metastases reduction, and the modulation of oxidative stress. MG-<i>Pe</i> binds to galectin-3. Furthermore, MG-<i>Pe</i> antitumor effects were substantially reduced in Gal-3/KO mice. Our results showed that the novel Gal-3 ligand, MG-<i>Pe,</i> has both antitumor and antimetastatic effects, alone or in combination with chemotherapy."]}, "AuthorList": [{"Identifier": ["0000-0002-4110-4354"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cellular Biology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Biscaia", "ForeName": "Stellee M P", "Initials": "SMP"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, Biopol, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Pires", "ForeName": "Cassiano", "Initials": "C"}, {"Identifier": ["0000-0001-6533-0850"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Post-Graduate Program in Medicinal Plants and Phytotherapics in Basic Attention, Parana University (UNIPAR), Umuarama 87502-210, Brazil."}], "LastName": "L\u00edvero", "ForeName": "Francislaine A R", "Initials": "FAR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cellular Biology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Bellan", "ForeName": "Daniel L", "Initials": "DL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cellular Biology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Bini", "ForeName": "Israel", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Radiology and Oncology, Faculty of Medicine, Center for Translational Research in Oncology (CTO), Cancer Institute of the State of S\u00e3o Paulo, University of S\u00e3o Paulo (USP), S\u00e3o Paulo 01246-000, Brazil."}], "LastName": "Bustos", "ForeName": "Silvina O", "Initials": "SO"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Radiology and Oncology, Faculty of Medicine, Center for Translational Research in Oncology (CTO), Cancer Institute of the State of S\u00e3o Paulo, University of S\u00e3o Paulo (USP), S\u00e3o Paulo 01246-000, Brazil."}], "LastName": "Vasconcelos", "ForeName": "Renata O", "Initials": "RO"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Acco", "ForeName": "Alexandra", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Iacomini", "ForeName": "Marcello", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chemistry, Federal University of Catal\u00e3o (UFCAT), Catal\u00e3o 75704-020, Brazil."}], "LastName": "Carbonero", "ForeName": "Elaine R", "Initials": "ER"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Analyses, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo (USP), Ribeir\u00e3o Preto 14040-903, Brazil."}], "LastName": "Amstalden", "ForeName": "Martin K", "Initials": "MK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Analyses, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo (USP), Ribeir\u00e3o Preto 14040-903, Brazil."}], "LastName": "Kubata", "ForeName": "F\u00e1bio R", "Initials": "FR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA."}], "LastName": "Cummings", "ForeName": "Richard D", "Initials": "RD"}, {"Identifier": ["0000-0002-2039-1884"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Analyses, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto, University of S\u00e3o Paulo (USP), Ribeir\u00e3o Preto 14040-903, Brazil."}], "LastName": "Dias-Baruffi", "ForeName": "Marcelo", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cellular Biology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Simas", "ForeName": "Fernanda F", "Initials": "FF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cellular Biology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Oliveira", "ForeName": "Carolina C", "Initials": "CC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, Biopol, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Freitas", "ForeName": "Rilton A", "Initials": "RA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cellular Biology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Franco", "ForeName": "C\u00e9lia Regina Cavichiolo", "Initials": "CRC"}, {"Identifier": ["0000-0003-0342-8726"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Radiology and Oncology, Faculty of Medicine, Center for Translational Research in Oncology (CTO), Cancer Institute of the State of S\u00e3o Paulo, University of S\u00e3o Paulo (USP), S\u00e3o Paulo 01246-000, Brazil."}], "LastName": "Chammas", "ForeName": "Roger", "Initials": "R"}, {"Identifier": ["0000-0002-8051-6298"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cellular Biology, Federal University of Paran\u00e1 (UFPR), Curitiba 81531-980, Brazil."}], "LastName": "Trindade", "ForeName": "Edvaldo S", "Initials": "ES"}], "GrantList": [{"GrantID": "CNPq 305700/2017-0; 315297/2021-2; 310290/2021-0; 312606/2019-2", "Agency": "National Council for Scientific and Technological Development", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Galectin 3"}, {"RegistryNumber": "0", "NameOfSubstance": "Ligands"}, {"RegistryNumber": "7GR28W0FJI", "NameOfSubstance": "Dacarbazine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["metabolism", "pharmacology", "therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["metabolism", "pharmacology", "therapeutic use"], "DescriptorName": "Dacarbazine"}, {"QualifierName": ["metabolism", "pharmacology", "therapeutic use"], "DescriptorName": "Galectin 3"}, {"QualifierName": [], "DescriptorName": "Ligands"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Melanoma"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Neoplasm Recurrence, Local"}, {"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Skin Neoplasms"}, {"QualifierName": ["drug effects", "physiology"], "DescriptorName": "Tumor Microenvironment"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "WHO\u2014World Health Organization.  [(accessed on 28 March 2022)].  Available online:  https://www.who.int/en/news-room/fact-sheets/detail/cancer."}, {"Citation": "WHO  WHO|Skin Cancers.  [(accessed on 19 April 2022)].  Available online:  http://www.who.int/uv/faq/skincancer/en/index1.html."}, {"Citation": "Sandru A., Voinea S., Panaitescu E., Blidaru A. Survival rates of patients with metastatic malignant melanoma. J. Med. Life. 2014;7:572\u2013576.", "ArticleIdList": ["PMC4316142", "25713625"]}, {"Citation": "Mishra H., Mishra P.K., Ekielski A., Jaggi M., Iqbal Z., Talegaonkar S. Melanoma treatment: From conventional to nanotechnology. J. Cancer Res. Clin. Oncol. 2018;144:2283\u20132302. doi: 10.1007/s00432-018-2726-1.", "ArticleIdList": ["10.1007/s00432-018-2726-1", "30094536"]}, {"Citation": "Domingues B., Lopes J., Soares P., Populo H. Melanoma treatment in review. ImmunoTargets Ther. 2018;7:35\u201349. doi: 10.2147/ITT.S134842.", "ArticleIdList": ["10.2147/ITT.S134842", "PMC5995433", "29922629"]}, {"Citation": "Minist\u00e9rio da Sa\u00fade do Brasil  . Portaria n\u00b0 357 de 8 de abril de 2013-Diretrizes Diagn\u00f3sticas e Terap\u00eauticas do Melanoma Maligno Cut\u00e2neo. Minist\u00e9rio da Sa\u00fade do Brasil; Brazil: 2013.  [(accessed on 4 July 2022)]. p. 16. Available online:  https://bvsms.saude.gov.br/bvs/saudelegis/sas/2013/prt0357_08_04_2013.html."}, {"Citation": "de Miranda Corr\u00eaa F., Guerra R.L., Fernandes R.R.A., Souza M.C.D., Zimmermann I.R. Terapia-alvo versus dacarbazina no tratamento de primeira linha do melanoma avan\u00e7ado n\u00e3o cir\u00fargico e metast\u00e1tico: An\u00e1lise de impacto or\u00e7ament\u00e1rio na perspectiva do Sistema \u00danico de Sa\u00fade, 2018\u20132020*. Epidemiol. Servi\u00e7os Sa\u00fade. 2019;28:e2018325. doi: 10.5123/S1679-49742019000200013.", "ArticleIdList": ["10.5123/S1679-49742019000200013", "31271637"]}, {"Citation": "Guerra R.L., de Miranda Corr\u00eaa F., Fernandes R.R.A., Zimmerman I.R. Cost Utility of Target Therapies Compared to Dacarbazine for First-Line Treatment of Advanced Non-Surgical and Metastatic Melanoma in the Brazilian National Health System. Value Health Reg. Issues. 2019;20:103\u2013109. doi: 10.1016/j.vhri.2019.04.001.", "ArticleIdList": ["10.1016/j.vhri.2019.04.001", "31174179"]}, {"Citation": "Al-Badr A.A., Alodhaib M.M. Dacarbazine. Profiles Drug Subst. Excip. Relat. Methodol. 2016;41:323\u2013377.", "ArticleIdList": ["26940170"]}, {"Citation": "Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2015;380:205\u2013215. doi: 10.1016/j.canlet.2015.07.044.", "ArticleIdList": ["10.1016/j.canlet.2015.07.044", "26272180"]}, {"Citation": "Arneth B. Tumor Microenvironment. Medicina. 2019;56:15. doi: 10.3390/medicina56010015.", "ArticleIdList": ["10.3390/medicina56010015", "PMC7023392", "31906017"]}, {"Citation": "Falcone I., Conciatori F., Bazzichetto C., Ferretti G., Cognetti F., Ciuffreda L., Milella M. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers. 2020;12:2870. doi: 10.3390/cancers12102870.", "ArticleIdList": ["10.3390/cancers12102870", "PMC7601592", "33036192"]}, {"Citation": "Marusyk A., Janiszewska M., Polyak K. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell. 2020;37:471\u2013484. doi: 10.1016/j.ccell.2020.03.007.", "ArticleIdList": ["10.1016/j.ccell.2020.03.007", "PMC7181408", "32289271"]}, {"Citation": "Jardim D.L., De Melo Gagliato D., Nikanjam M., Barkauskas D.A., Kurzrock R. Efficacy and safety of anticancer drug combinations: A meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncoimmunology. 2020;9:1710052. doi: 10.1080/2162402X.2019.1710052.", "ArticleIdList": ["10.1080/2162402X.2019.1710052", "PMC6959453", "32002305"]}, {"Citation": "Biscaia S.M.P., Carbonero E.R., Bellan D.L., Borges B.S., Costa C.R., Rossi G.R., Gon\u00e7alves J.P., Melo C.M., L\u00edvero F.A.R., Ruthes A.C., et al. Safe therapeutics of murine melanoma model using a novel antineoplasic, the partially methylated mannogalactan from Pleurotus eryngii. Carbohydr. Polym. 2017;178:95\u2013104. doi: 10.1016/j.carbpol.2017.08.117.", "ArticleIdList": ["10.1016/j.carbpol.2017.08.117", "29050620"]}, {"Citation": "Nangia-Makker P., Hogan V., Raz A. Galectin-3 and cancer stemness. Glycobiology. 2018;28:172\u2013181. doi: 10.1093/glycob/cwy001.", "ArticleIdList": ["10.1093/glycob/cwy001", "PMC6279147", "29315388"]}, {"Citation": "Brown E.R., Doig T., Anderson N., Brenn T., Doherty V., Xu Y., Bartlett J.M.S., Smyth J.F., Melton D.W. Association of galectin-3 expression with melanoma progression and prognosis. Eur. J. Cancer. 2012;48:865\u2013874. doi: 10.1016/j.ejca.2011.09.003.", "ArticleIdList": ["10.1016/j.ejca.2011.09.003", "22071132"]}, {"Citation": "Braeuer R.R., Zigler M., Kamiya T., Dobroff A.S., Huang L., Choi W., McConkey D.J., Shoshan E., Mobley A.K., Song R., et al. Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin. Cancer Res. 2012;72:5757\u20135766. doi: 10.1158/0008-5472.CAN-12-2424.", "ArticleIdList": ["10.1158/0008-5472.CAN-12-2424", "PMC3500452", "22986745"]}, {"Citation": "Fortuna-Costa A., Gomes A.M., Kozlowski E.O., Stelling M.P., Pav\u00c3\u00a3o M.S.G. Extracellular Galectin-3 in Tumor Progression and Metastasis. Front. Oncol. 2014;4:138. doi: 10.3389/fonc.2014.00138.", "ArticleIdList": ["10.3389/fonc.2014.00138", "PMC4058817", "24982845"]}, {"Citation": "Comodo A.N., Soares M.F., de Paulo Castro Teixeira V., Franco M., Lacerda Bachi A.L. Galectin-3 expression favors metastasis in murine melanoma. Adv. Biosci. Biotechnol. 2013;4:55\u201362. doi: 10.4236/abb.2013.410A3007.", "ArticleIdList": ["10.4236/abb.2013.410A3007"]}, {"Citation": "Harazono Y., Kho D.H., Balan V., Nakajima K., Hogan V., Raz A. Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget. 2015;6:19592\u201319604. doi: 10.18632/oncotarget.4285.", "ArticleIdList": ["10.18632/oncotarget.4285", "PMC4637307", "26158764"]}, {"Citation": "Takenaka Y., Fukumori T., Raz A. Galectin-3 and metastasis. Glycoconj. J. 2002;19:543\u2013549. doi: 10.1023/B:GLYC.0000014084.01324.15.", "ArticleIdList": ["10.1023/B:GLYC.0000014084.01324.15", "14758078"]}, {"Citation": "Ahmed H., Guha P., Kaptan E., Bandyopadhyaya G. Galectin-3: A potential target for cancer prevention. Trends Carbohydr. Res. 2011;3:13\u201322. doi: 10.4137/CMO.S29462.", "ArticleIdList": ["10.4137/CMO.S29462", "PMC4254724", "25484547"]}, {"Citation": "Jeethy Ram T., Lekshmi A., Somanathan T., Sujathan K. Galectin-3: A factotum in carcinogenesis bestowing an archery for prevention. Tumour Biol. 2021;43:77\u201396. doi: 10.3233/TUB-200051.", "ArticleIdList": ["10.3233/TUB-200051", "33998569"]}, {"Citation": "Ikemori R.Y., Machado C.M.L., Furuzawa K.M., Nonogaki S., Osinaga E., Umezawa K., De Carvalho M.A., Verinaud L., Chammas R. Galectin-3 up-regulation in hypoxic and nutrient deprived microenvironments promotes cell survival. PLoS ONE. 2014;9:e111592. doi: 10.1371/journal.pone.0111592.", "ArticleIdList": ["10.1371/journal.pone.0111592", "PMC4219723", "25369297"]}, {"Citation": "Rahimian R., B\u00e9land L.C., Sato S., Kriz J. Microglia-derived galectin-3 in neuroinflammation; a bittersweet ligand? Med. Res. Rev. 2021;41:2582\u20132589. doi: 10.1002/med.21784.", "ArticleIdList": ["10.1002/med.21784", "33733487"]}, {"Citation": "Rahimian R., B\u00e9land L.C., Kriz J. Galectin-3: Mediator of microglia responses in injured brain. Drug Discov. Today. 2018;23:375\u2013381. doi: 10.1016/j.drudis.2017.11.004.", "ArticleIdList": ["10.1016/j.drudis.2017.11.004", "29133191"]}, {"Citation": "Rahimian R., Lively S., Abdelhamid E., Lalancette-Hebert M., Schlichter L., Sato S., Kriz J. Delayed Galectin-3-Mediated Reprogramming of Microglia After Stroke is Protective. Mol. Neurobiol. 2019;56:6371\u20136385. doi: 10.1007/s12035-019-1527-0.", "ArticleIdList": ["10.1007/s12035-019-1527-0", "30798442"]}, {"Citation": "Wdowiak K., Francuz T., Gallego-Colon E., Ruiz-Agamez N., Kubeczko M., Grocho\u0142a I., Wojnar J. Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives. Int. J. Mol. Sci. 2018;19:210. doi: 10.3390/ijms19010210.", "ArticleIdList": ["10.3390/ijms19010210", "PMC5796159", "29320431"]}, {"Citation": "Blanchard H., Yu X., Collins P.M., Bum-Erdene K. Galectin-3 inhibitors: A patent review (2008\u2013present) Expert Opin. Ther. Pat. 2014;24:1053\u20131065. doi: 10.1517/13543776.2014.947961.", "ArticleIdList": ["10.1517/13543776.2014.947961", "25109359"]}, {"Citation": "NIH  Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients with Metastatic Melanoma-NCT02117362.  [(accessed on 23 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/study/NCT02117362?term=gr-md-02&cond=cancer&draw=2&rank=3."}, {"Citation": "Lee Y. Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp. Cell Res. 2003;288:21\u201334. doi: 10.1016/S0014-4827(03)00211-8.", "ArticleIdList": ["10.1016/S0014-4827(03)00211-8", "12878156"]}, {"Citation": "Wu W.-S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006;25:695\u2013705. doi: 10.1007/s10555-006-9037-8.", "ArticleIdList": ["10.1007/s10555-006-9037-8", "17160708"]}, {"Citation": "Ziech D., Franco R., Pappa A., Panayiotidis M.I. Reactive Oxygen Species (ROS)\u2013\u2013Induced genetic and epigenetic alterations in human carcinogenesis. Mutat. Res. Mol. Mech. Mutagen. 2011;711:167\u2013173. doi: 10.1016/j.mrfmmm.2011.02.015.", "ArticleIdList": ["10.1016/j.mrfmmm.2011.02.015", "21419141"]}, {"Citation": "Liu-Smith F., Dellinger R., Meyskens F.L. Updates of reactive oxygen species in melanoma etiology and progression. Arch. Biochem. Biophys. 2014;563:51\u201355. doi: 10.1016/j.abb.2014.04.007.", "ArticleIdList": ["10.1016/j.abb.2014.04.007", "PMC4209333", "24780245"]}, {"Citation": "Sander C.S., Hamm F., Elsner P., Thiele J.J. Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br. J. Dermatol. 2003;148:913\u2013922. doi: 10.1046/j.1365-2133.2003.05303.x.", "ArticleIdList": ["10.1046/j.1365-2133.2003.05303.x", "12786821"]}, {"Citation": "Milkovic L., Cipak Gasparovic A., Cindric M., Mouthuy P.-A., Zarkovic N. Short Overview of ROS as Cell Function Regulators and Their Implications in Therapy Concepts. Cells. 2019;8:793. doi: 10.3390/cells8080793.", "ArticleIdList": ["10.3390/cells8080793", "PMC6721558", "31366062"]}, {"Citation": "Wittgen H.G.M., van Kempen L.C.L.T. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res. 2007;17:400\u2013409. doi: 10.1097/CMR.0b013e3282f1d312.", "ArticleIdList": ["10.1097/CMR.0b013e3282f1d312", "17992124"]}, {"Citation": "NIH  Safety of GM-CT-01 with and without 5-Fluorouracil in Patients with Solid Tumors-NCT00054977.  [(accessed on 23 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT00054977?term=gm-ct-01&cond=cancer&draw=2&rank=4."}, {"Citation": "Platt D., Klyosov A. Patent-Selectively Depolymerized Galactomannan Polysaccharide. No. 7,893,252 B2.  [(accessed on 4 July 2022)];U.S. Patent. 2011 February 22; Available online:  https://patentimages.storage.googleapis.com/79/ad/80/04ce3e1adad964/US7893252.pdf."}, {"Citation": "NIH  A Phase III Study to Investigate Toripalimab versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma-NCT03430297.  [(accessed on 23 June 2022)]; Available online:  https://www.clinicaltrials.gov/ct2/show/NCT03430297?cond=dacarbazine&draw=2&rank=6."}, {"Citation": "Jiang G., Li R.-H., Sun C., Liu Y.-Q., Zheng J.-N. Dacarbazine Combined Targeted Therapy versus Dacarbazine Alone in Patients with Malignant Melanoma: A Meta-Analysis. PLoS ONE. 2014;9:e111920. doi: 10.1371/journal.pone.0111920.", "ArticleIdList": ["10.1371/journal.pone.0111920", "PMC4263472", "25502446"]}, {"Citation": "Adami E.R., Corso C.R., Turin-Oliveira N.M., Galindo C.M., Milani L., Stipp M.C., da Silva L.C.M., do Nascimento G.E., Chaves P.F.P., Chequin A., et al. Polysaccharides from green sweet pepper increase the antineoplastic effect of methotrexate on mammary tumor cells. Int. J. Biol. Macromol. 2020;158:1071\u20131081. doi: 10.1016/j.ijbiomac.2020.05.001.", "ArticleIdList": ["10.1016/j.ijbiomac.2020.05.001", "32387356"]}, {"Citation": "Davis L.E., Shalin S.C., Tackett A.J. Current state of melanoma diagnosis and treatment. Cancer Biol. Ther. 2019;20:1366\u20131379. doi: 10.1080/15384047.2019.1640032.", "ArticleIdList": ["10.1080/15384047.2019.1640032", "PMC6804807", "31366280"]}, {"Citation": "Bellan D.L., Biscaia S.M.P., Rossi G.R., Cristal A.M., Gon\u00e7alves J.P., Oliveira C.C., Simas F.F., Sabry D.A., Rocha H.A.O., Franco C.R.C., et al. Green does not always mean go: A sulfated galactan from Codium isthmocladum green seaweed reduces melanoma metastasis through direct regulation of malignancy features. Carbohydr. Polym. 2020;250:116869. doi: 10.1016/j.carbpol.2020.116869.", "ArticleIdList": ["10.1016/j.carbpol.2020.116869", "33049818"]}, {"Citation": "Bellan D.L., Mazepa E., Biscaia S.M.P., Gon\u00e7alves J.P., Oliveira C.C., Rossi G.R., Ferreira L.G., Noseda M.D., Trindade E.S., Duarte M.E.R., et al. Non-Cytotoxic Sulfated Heterorhamnan from Gayralia brasiliensis Green Seaweed Reduces Driver Features of Melanoma Metastatic Progression. Mar. Biotechnol. 2020;22:194\u2013206. doi: 10.1007/s10126-020-09944-9.", "ArticleIdList": ["10.1007/s10126-020-09944-9", "31970542"]}, {"Citation": "Yan J., Meng Y., Zhang M., Zhou X., Cheng H., Sun L., Zhou Y. A 3-O-methylated heterogalactan from Pleurotus eryngii activates macrophages. Carbohydr. Polym. 2019;206:706\u2013715. doi: 10.1016/j.carbpol.2018.11.063.", "ArticleIdList": ["10.1016/j.carbpol.2018.11.063", "30553376"]}, {"Citation": "Nesmelova I.V., Dings R.P.M., Mayo K.H. Galectins. John Wiley & Sons, Inc.; Hoboken, NJ, USA: 2008. Understanding Galectin Structure\u2013Function Relationships to Design Effective Antagonists; pp. 33\u201369."}, {"Citation": "Miller M.C., Klyosov A., Mayo K.H. The \u03b1-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain. Glycobiology. 2009;19:1034\u20131045. doi: 10.1093/glycob/cwp084.", "ArticleIdList": ["10.1093/glycob/cwp084", "PMC2720280", "19541770"]}, {"Citation": "Sethi A., Sanam S., Alvala R., Alvala M. An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016\u2013present) Expert Opin. Ther. Pat. 2021;31:709\u2013721. doi: 10.1080/13543776.2021.1903430.", "ArticleIdList": ["10.1080/13543776.2021.1903430", "33749494"]}, {"Citation": "Zhang B., Li Y., Zhang F., Linhardt R.J., Zeng G., Zhang A. Extraction, structure and bioactivities of the polysaccharides from Pleurotus eryngii: A review. Int. J. Biol. Macromol. 2020;150:1342\u20131347. doi: 10.1016/j.ijbiomac.2019.10.144.", "ArticleIdList": ["10.1016/j.ijbiomac.2019.10.144", "31759001"]}, {"Citation": "Miller M.C., Ippel H., Suylen D., Klyosov A.A., Traber P.G., Hackeng T., Mayo K.H. Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain. Glycobiology. 2015;26:88\u201399. doi: 10.1093/glycob/cwv073.", "ArticleIdList": ["10.1093/glycob/cwv073", "PMC4851716", "26646771"]}, {"Citation": "Hara A., Niwa M., Noguchi K., Kanayama T., Niwa A., Matsuo M., Hatano Y., Tomita H. Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules. 2020;10:389. doi: 10.3390/biom10030389.", "ArticleIdList": ["10.3390/biom10030389", "PMC7175224", "32138174"]}, {"Citation": "Capone E., Iacobelli S., Sala G. Role of galectin 3 binding protein in cancer progression: A potential novel therapeutic target. J. Transl. Med. 2021;19:1\u201318. doi: 10.1186/s12967-021-03085-w.", "ArticleIdList": ["10.1186/s12967-021-03085-w", "PMC8474792", "34565385"]}, {"Citation": "Newlaczyl A.U., Yu L.-G. Galectin-3\u2014A jack-of-all-trades in cancer. Cancer Lett. 2011;313:123\u2013128. doi: 10.1016/j.canlet.2011.09.003.", "ArticleIdList": ["10.1016/j.canlet.2011.09.003", "21974805"]}, {"Citation": "Yao Y., Zhou L., Liao W., Chen H., Du Z., Shao C., Wang P., Ding K. HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway. Carbohydr. Polym. 2019;204:111\u2013123. doi: 10.1016/j.carbpol.2018.10.008.", "ArticleIdList": ["10.1016/j.carbpol.2018.10.008", "30366522"]}, {"Citation": "Zhang L., Wang P., Qin Y., Cong Q., Shao C., Du Z., Ni X., Li P., Ding K. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways. Oncogene. 2017;36:1297\u20131308. doi: 10.1038/onc.2016.306.", "ArticleIdList": ["10.1038/onc.2016.306", "27617577"]}, {"Citation": "Cardoso A.C.F., de Sousa Andrade L.N., Bustos S.O., Chammas R. Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments. Front. Oncol. 2016;6:127. doi: 10.3389/fonc.2016.00127.", "ArticleIdList": ["10.3389/fonc.2016.00127", "PMC4876484", "27242966"]}, {"Citation": "Machado C.M.L., Andrade L.N.S., Teixeira V.R., Costa F.F., Melo C.M., dos Santos S.N., Nonogaki S., Liu F.T., Bernardes E.S., Camargo A.A., et al. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFb1-induced macrophages. Cancer Med. 2014;3:201\u2013214. doi: 10.1002/cam4.173.", "ArticleIdList": ["10.1002/cam4.173", "PMC3987071", "24421272"]}, {"Citation": "NIH  . Dacarbazine. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA: 2017.  [(accessed on 4 July 2022)].  Available online:  https://www.ncbi.nlm.nih.gov/books/NBK548913/"}, {"Citation": "Woiniak A., Drewa G., Wo\u017aniak B., Schachtschabel D.O., Mila-Kierzenkowska C., Drewa T., Olszewska-S\u0142onina D., Sopo\u0144ska M. The effect of antitumor drugs on oxidative stress in B16 and S91 melanoma cells in vitro. Med. Sci. Monit. 2005;11:BR22\u2013BR29.", "ArticleIdList": ["15614186"]}, {"Citation": "Deneke S.M., Fanburg B.L. Regulation of cellular glutathione. Am. J. Physiol. Cell. Mol. Physiol. 1989;257:L163\u2013L173. doi: 10.1152/ajplung.1989.257.4.L163.", "ArticleIdList": ["10.1152/ajplung.1989.257.4.L163", "2572174"]}, {"Citation": "Gat\u00e9 L., Paul J., Ba G.N., Tew K.D., Tapiero H. Oxidative stress induced in pathologies: The role of antioxidants. Biomed. Pharmacother. 1999;53:169\u2013180. doi: 10.1016/S0753-3322(99)80086-9.", "ArticleIdList": ["10.1016/S0753-3322(99)80086-9", "10392289"]}, {"Citation": "Barrera G. Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy. ISRN Oncol. 2012;2012:137289. doi: 10.5402/2012/137289.", "ArticleIdList": ["10.5402/2012/137289", "PMC3483701", "23119185"]}, {"Citation": "Landriscina M., Maddalena F., Laudiero G., Esposito F. Adaptation to Oxidative Stress, Chemoresistance, and Cell Survival. Antioxid. Redox Signal. 2009;11:2701\u20132716. doi: 10.1089/ars.2009.2692.", "ArticleIdList": ["10.1089/ars.2009.2692", "19778285"]}, {"Citation": "Traverso N., Ricciarelli R., Nitti M., Marengo B., Furfaro A.L., Pronzato M.A., Marinari U.M., Domenicotti C. Role of Glutathione in Cancer Progression and Chemoresistance. Oxid. Med. Cell. Longev. 2013;2013:1\u201310. doi: 10.1155/2013/972913.", "ArticleIdList": ["10.1155/2013/972913", "PMC3673338", "23766865"]}, {"Citation": "Calvert P., Yao K.-S., Hamilton T.C., O\u2019Dwyer P.J. Clinical studies of reversal of drug resistance based on glutathione. Chem. Biol. Interact. 1998;111\u2013112:213\u2013224. doi: 10.1016/S0009-2797(98)00008-8.", "ArticleIdList": ["10.1016/S0009-2797(98)00008-8", "9679556"]}, {"Citation": "Estrela J.M., Ortega A., Obrador E. Glutathione in Cancer Biology and Therapy. Crit. Rev. Clin. Lab. Sci. 2006;43:143\u2013181. doi: 10.1080/10408360500523878.", "ArticleIdList": ["10.1080/10408360500523878", "16517421"]}, {"Citation": "De Visser K.E., Jonkers J. Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance. Curr. Pharm. Des. 2009;15:1844\u20131853. doi: 10.2174/138161209788453239.", "ArticleIdList": ["10.2174/138161209788453239", "19519427"]}, {"Citation": "Glasauer A., Chandel N.S. Targeting antioxidants for cancer therapy. Biochem. Pharmacol. 2014;92:90\u2013101. doi: 10.1016/j.bcp.2014.07.017.", "ArticleIdList": ["10.1016/j.bcp.2014.07.017", "25078786"]}, {"Citation": "Matarrese P., Tinari N., Semeraro M.L., Natoli C., Iacobelli S., Malorni W. Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett. 2000;473:311\u2013315. doi: 10.1016/S0014-5793(00)01547-7.", "ArticleIdList": ["10.1016/S0014-5793(00)01547-7", "10818231"]}, {"Citation": "Li Y.-S., Li X.-T., Yu L.-G., Wang L., Shi Z.-Y., Guo X.-L. Roles of galectin-3 in metabolic disorders and tumor cell metabolism. Int. J. Biol. Macromol. 2020;142:463\u2013473. doi: 10.1016/j.ijbiomac.2019.09.118.", "ArticleIdList": ["10.1016/j.ijbiomac.2019.09.118", "31604080"]}, {"Citation": "Moon B.-K., Lee Y.J., Battle P., Jessup J.M., Raz A., Kim H.-R.C. Galectin-3 Protects Human Breast Carcinoma Cells against Nitric Oxide-Induced Apoptosis. Am. J. Pathol. 2001;159:1055\u20131060. doi: 10.1016/S0002-9440(10)61780-4.", "ArticleIdList": ["10.1016/S0002-9440(10)61780-4", "PMC1850442", "11549597"]}, {"Citation": "Song Y.K., Billiar T.R., Lee Y.J. Role of Galectin-3 in Breast Cancer Metastasis. Am. J. Pathol. 2002;160:1069\u20131075. doi: 10.1016/S0002-9440(10)64927-9.", "ArticleIdList": ["10.1016/S0002-9440(10)64927-9", "PMC1867157", "11891203"]}, {"Citation": "Sun W., Li L., Li L.J., Yang Q.Q., Zhang Z.R., Huang Y. Two birds, one stone: Dual targeting of the cancer cell surface and subcellular mitochondria by the galectin-3-binding peptide G3-C12. Acta Pharmacol. Sin. 2017;38:806\u2013822. doi: 10.1038/aps.2016.137.", "ArticleIdList": ["10.1038/aps.2016.137", "PMC5520179", "28065935"]}, {"Citation": "Mishra S., Tamta A.K., Sarikhani M., Desingu P.A., Kizkekra S.M., Pandit A.S., Kumar S., Khan D., Raghavan S.C., Sundaresan N.R. Subcutaneous Ehrlich Ascites Carcinoma mice model for studying cancer-induced cardiomyopathy. Sci. Rep. 2018;8:5599. doi: 10.1038/s41598-018-23669-9.", "ArticleIdList": ["10.1038/s41598-018-23669-9", "PMC5884778", "29618792"]}, {"Citation": "Hsu D.K., Yang R.-Y., Pan Z., Yu L., Salomon D.R., Fung-Leung W.-P., Liu F.-T. Targeted Disruption of the Galectin-3 Gene Results in Attenuated Peritoneal Inflammatory Responses. Am. J. Pathol. 2000;156:1073\u20131083. doi: 10.1016/S0002-9440(10)64975-9.", "ArticleIdList": ["10.1016/S0002-9440(10)64975-9", "PMC1876862", "10702423"]}, {"Citation": "Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman\u2019s reagent. Anal. Biochem. 1968;25:192\u2013205. doi: 10.1016/0003-2697(68)90092-4.", "ArticleIdList": ["10.1016/0003-2697(68)90092-4", "4973948"]}, {"Citation": "Jiang Z.-Y., Hunt J.V., Wolff S.P. Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal. Biochem. 1992;202:384\u2013389. doi: 10.1016/0003-2697(92)90122-N.", "ArticleIdList": ["10.1016/0003-2697(92)90122-N", "1519766"]}, {"Citation": "Biscaia S.M.P., Carbonero E.R., Trindade E.S., Franco C.R.C., de Oliveira C.C., Chammas R., Iacomini M. Patent application: Manogalactana parcialmente metilada de cogumelo Pleurotus eryngii possui atividade antitumoral-BR 102018005595-0 A2. 2018.  [(accessed on 4 July 2022)].  Available online:  https://spin.ufpr.br/wp-content/uploads/2022/03/Publicacao_PI0458_BR1020180055950.pdf."}, {"Citation": "Salomonsson E., Thijssen V.L., Griffioen A.W., Nilsson U.J., Leffler H. The Anti-angiogenic Peptide Anginex Greatly Enhances Galectin-1 Binding Affinity for Glycoproteins. J. Biol. Chem. 2011;286:13801\u201313804. doi: 10.1074/jbc.C111.229096.", "ArticleIdList": ["10.1074/jbc.C111.229096", "PMC3077580", "21372130"]}, {"Citation": "Dings R.P.M., Kumar N., Miller M.C., Loren M., Rangwala H., Hoye T.R., Mayo K.H. Structure-Based Optimization of Angiostatic Agent 6DBF7, an Allosteric Antagonist of Galectin-1. J. Pharmacol. Exp. Ther. 2013;344:589\u2013599. doi: 10.1124/jpet.112.199646.", "ArticleIdList": ["10.1124/jpet.112.199646", "PMC3583509", "23232447"]}, {"Citation": "Astorgues-Xerri L., Riveiro M.E., Tijeras-Raballand A., Serova M., Rabinovich G.A., Bieche I., Vidaud M., de Gramont A., Martinet M., Cvitkovic E., et al. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. Eur. J. Cancer. 2014;50:2463\u20132477. doi: 10.1016/j.ejca.2014.06.015.", "ArticleIdList": ["10.1016/j.ejca.2014.06.015", "25042151"]}, {"Citation": "Dings R.P.M., Miller M.C., Nesmelova I., Astorgues-Xerri L., Kumar N., Serova M., Chen X., Raymond E., Hoye T.R., Mayo K.H. Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding. J. Med. Chem. 2012;55:5121\u20135129. doi: 10.1021/jm300014q.", "ArticleIdList": ["10.1021/jm300014q", "PMC4242090", "22575017"]}, {"Citation": "NIH  Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis-NCT04365868.  [(accessed on 23 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04365868."}, {"Citation": "Fang T., Liu D., Ning H., Liu D., Sun J., Huang X., Dong Y., Geng M., Yun S., Yan J., et al. Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3. Acta Pharmacol. Sin. 2018;39:1885\u20131893. doi: 10.1038/s41401-018-0004-z.", "ArticleIdList": ["10.1038/s41401-018-0004-z", "PMC6289393", "29769742"]}, {"Citation": "NIH  A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)-NCT03832946.  [(accessed on 23 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT03832946."}, {"Citation": "NIH  DEFINE-Evaluating Therapies for COVID-19-NCT04473053.  [(accessed on 23 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04473053."}, {"Citation": "NIH  A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects-NCT03809052.  [(accessed on 23 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT03809052."}, {"Citation": "NIH  Galecto\u2019s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific Conferences\u2014Galecto, Inc.  [(accessed on 23 June 2022)].  Available online:  https://galecto.com/gb1211-data/"}, {"Citation": "NIH  Study of Efficacy and Safety of MBG453 in Combination with Azacitidine in Subjects with Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)-NCT04266301.  [(accessed on 23 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04266301."}, {"Citation": "NIH  A Study of MBG453 in Combination with Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy-NCT04150029.  [(accessed on 23 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04150029."}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "6", "Day": "1"}, {"Year": "2022", "Month": "7", "Day": "5"}, {"Year": "2022", "Month": "7", "Day": "5"}, {"Year": "2022", "Month": "7", "Day": "27", "Hour": "1", "Minute": "22"}, {"Year": "2022", "Month": "7", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "11"}], "PublicationStatus": "epublish", "ArticleIdList": ["35886983", "PMC9317553", "10.3390/ijms23147635", "ijms23147635"]}}], "PubmedBookArticle": []}